Do analysts prefer NRXP or TAOX?

NRx Pharmaceuticals currently has a consensus target price of $34.50, suggesting a potential upside of 1,177.78%. Given NRx Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe NRx Pharmaceuticals is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NRx Pharmaceuticals 2 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.43 Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer VTVT or TAOX?

vTv Therapeutics presently has a consensus price target of $55.83, suggesting a potential upside of 97.78%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe vTv Therapeutics is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score vTv Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78 Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to VTVT or TAOX?

In the previous week, vTv Therapeutics had 6 more articles in the media than Synaptogenix. MarketBeat recorded 9 mentions for vTv Therapeutics and 3 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 0.37 beat vTv Therapeutics' score of 0.27 indicating that Synaptogenix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment vTv Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Synaptogenix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate BGM or TAOX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, BGM or TAOX?

BGM Group has higher revenue and earnings than Synaptogenix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BGM Group $37.92M 3.37 -$19.94M N/A N/A Synaptogenix $300K 96.29 -$28.74M -$3.85 N/A

Do analysts rate UNCY or TAOX?

Unicycive Therapeutics presently has a consensus target price of $18.25, indicating a potential upside of 389.28%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Unicycive Therapeutics is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Unicycive Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer UNCY or TAOX?

In the previous week, Unicycive Therapeutics had 8 more articles in the media than Synaptogenix. MarketBeat recorded 11 mentions for Unicycive Therapeutics and 3 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 0.37 beat Unicycive Therapeutics' score of 0.06 indicating that Synaptogenix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Unicycive Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Synaptogenix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate TAOX or AARD?

Aardvark Therapeutics has a consensus target price of $13.13, indicating a potential upside of 224.88%. Given Aardvark Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aardvark Therapeutics is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aardvark Therapeutics 2 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.36

Does the media prefer TAOX or AARD?

In the previous week, Aardvark Therapeutics had 23 more articles in the media than Synaptogenix. MarketBeat recorded 26 mentions for Aardvark Therapeutics and 3 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 0.37 beat Aardvark Therapeutics' score of 0.14 indicating that Synaptogenix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Synaptogenix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Aardvark Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 19 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Synaptogenix (TAOX) Competitors

$3.48 -0.20 (-5.30%)

As of 01:27 PM Eastern

Compare

TAOX vs. NRXP, VTVT, BGM, UNCY, and AARD

Should you buy Synaptogenix stock or one of its competitors? Synaptogenix's main competitors and comparable companies include NRx Pharmaceuticals (NRXP), vTv Therapeutics (VTVT), BGM Group (BGM), Unicycive Therapeutics (UNCY), and Aardvark Therapeutics (AARD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Synaptogenix compare to NRx Pharmaceuticals?

NRx Pharmaceuticals (NASDAQ:NRXP) and Synaptogenix (NASDAQ:TAOX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment.

In the previous week, Synaptogenix had 2 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 3 mentions for Synaptogenix and 1 mentions for NRx Pharmaceuticals. Synaptogenix's average media sentiment score of 0.37 beat NRx Pharmaceuticals' score of -0.26 indicating that Synaptogenix is being referred to more favorably in the news media.

Company	Overall Sentiment
NRx Pharmaceuticals	Neutral
Synaptogenix	Neutral

NRx Pharmaceuticals has higher revenue and earnings than Synaptogenix. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23M	95.05	-$28.62M	-$0.55	N/A
Synaptogenix	$300K	96.29	-$28.74M	-$3.85	N/A

NRx Pharmaceuticals currently has a consensus target price of $34.50, suggesting a potential upside of 1,177.78%. Given NRx Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe NRx Pharmaceuticals is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NRx Pharmaceuticals has a beta of 2.07, meaning that its stock price is 107% more volatile than the broader market. Comparatively, Synaptogenix has a beta of 1.73, meaning that its stock price is 73% more volatile than the broader market.

NRx Pharmaceuticals has a net margin of -691.81% compared to Synaptogenix's net margin of -2,153.97%. NRx Pharmaceuticals' return on equity of 0.00% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	-691.81%	N/A	-63.92%
Synaptogenix	-2,153.97%	-128.51%	-97.54%

4.3% of NRx Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.3% of Synaptogenix shares are owned by institutional investors. 6.4% of NRx Pharmaceuticals shares are owned by insiders. Comparatively, 2.7% of Synaptogenix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

NRx Pharmaceuticals beats Synaptogenix on 11 of the 16 factors compared between the two stocks.

How does Synaptogenix compare to vTv Therapeutics?

vTv Therapeutics (NASDAQ:VTVT) and Synaptogenix (NASDAQ:TAOX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

vTv Therapeutics has higher revenue and earnings than Synaptogenix. vTv Therapeutics is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	$1.02M	109.05	-$26.97M	-$1.06	N/A
Synaptogenix	$300K	96.29	-$28.74M	-$3.85	N/A

vTv Therapeutics has a net margin of 0.00% compared to Synaptogenix's net margin of -2,153.97%. vTv Therapeutics' return on equity of -6.27% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	-6.27%	-5.06%
Synaptogenix	-2,153.97%	-128.51%	-97.54%

17.5% of vTv Therapeutics shares are owned by institutional investors. Comparatively, 10.3% of Synaptogenix shares are owned by institutional investors. 6.0% of vTv Therapeutics shares are owned by company insiders. Comparatively, 2.7% of Synaptogenix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

vTv Therapeutics has a beta of 0.21, meaning that its share price is 79% less volatile than the broader market. Comparatively, Synaptogenix has a beta of 1.73, meaning that its share price is 73% more volatile than the broader market.

vTv Therapeutics presently has a consensus price target of $55.83, suggesting a potential upside of 97.78%. Given vTv Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe vTv Therapeutics is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, vTv Therapeutics had 6 more articles in the media than Synaptogenix. MarketBeat recorded 9 mentions for vTv Therapeutics and 3 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 0.37 beat vTv Therapeutics' score of 0.27 indicating that Synaptogenix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
vTv Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Synaptogenix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

vTv Therapeutics beats Synaptogenix on 14 of the 17 factors compared between the two stocks.

How does Synaptogenix compare to BGM Group?

BGM Group (NASDAQ:BGM) and Synaptogenix (NASDAQ:TAOX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

In the previous week, Synaptogenix had 1 more articles in the media than BGM Group. MarketBeat recorded 3 mentions for Synaptogenix and 2 mentions for BGM Group. BGM Group's average media sentiment score of 0.39 beat Synaptogenix's score of 0.37 indicating that BGM Group is being referred to more favorably in the media.

Company	Overall Sentiment
BGM Group	Neutral
Synaptogenix	Neutral

BGM Group has higher revenue and earnings than Synaptogenix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BGM Group	$37.92M	3.37	-$19.94M	N/A	N/A
Synaptogenix	$300K	96.29	-$28.74M	-$3.85	N/A

10.3% of Synaptogenix shares are owned by institutional investors. 58.7% of BGM Group shares are owned by insiders. Comparatively, 2.7% of Synaptogenix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BGM Group has a net margin of 0.00% compared to Synaptogenix's net margin of -2,153.97%. BGM Group's return on equity of 0.00% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BGM Group	N/A	N/A	N/A
Synaptogenix	-2,153.97%	-128.51%	-97.54%

BGM Group has a beta of 1.85, meaning that its share price is 85% more volatile than the broader market. Comparatively, Synaptogenix has a beta of 1.73, meaning that its share price is 73% more volatile than the broader market.

Summary

BGM Group beats Synaptogenix on 8 of the 11 factors compared between the two stocks.

How does Synaptogenix compare to Unicycive Therapeutics?

Unicycive Therapeutics (NASDAQ:UNCY) and Synaptogenix (NASDAQ:TAOX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 10.3% of Synaptogenix shares are owned by institutional investors. 6.0% of Unicycive Therapeutics shares are owned by insiders. Comparatively, 2.7% of Synaptogenix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Unicycive Therapeutics has a beta of 1.83, meaning that its stock price is 83% more volatile than the broader market. Comparatively, Synaptogenix has a beta of 1.73, meaning that its stock price is 73% more volatile than the broader market.

In the previous week, Unicycive Therapeutics had 8 more articles in the media than Synaptogenix. MarketBeat recorded 11 mentions for Unicycive Therapeutics and 3 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 0.37 beat Unicycive Therapeutics' score of 0.06 indicating that Synaptogenix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Unicycive Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Synaptogenix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Unicycive Therapeutics presently has a consensus target price of $18.25, indicating a potential upside of 389.28%. Given Unicycive Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Unicycive Therapeutics is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Unicycive Therapeutics has higher revenue and earnings than Synaptogenix. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	152.77	-$26.56M	-$1.75	N/A
Synaptogenix	$300K	96.29	-$28.74M	-$3.85	N/A

Unicycive Therapeutics has a net margin of 0.00% compared to Synaptogenix's net margin of -2,153.97%. Unicycive Therapeutics' return on equity of -91.50% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-91.50%	-61.47%
Synaptogenix	-2,153.97%	-128.51%	-97.54%

Summary

Unicycive Therapeutics beats Synaptogenix on 14 of the 16 factors compared between the two stocks.

How does Synaptogenix compare to Aardvark Therapeutics?

Synaptogenix (NASDAQ:TAOX) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

Aardvark Therapeutics has a net margin of 0.00% compared to Synaptogenix's net margin of -2,153.97%. Aardvark Therapeutics' return on equity of -71.54% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synaptogenix	-2,153.97%	-128.51%	-97.54%
Aardvark Therapeutics	N/A	-71.54%	-64.94%

Aardvark Therapeutics has a consensus target price of $13.13, indicating a potential upside of 224.88%. Given Aardvark Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aardvark Therapeutics is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.36

In the previous week, Aardvark Therapeutics had 23 more articles in the media than Synaptogenix. MarketBeat recorded 26 mentions for Aardvark Therapeutics and 3 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 0.37 beat Aardvark Therapeutics' score of 0.14 indicating that Synaptogenix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Synaptogenix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aardvark Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	19 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Synaptogenix has higher revenue and earnings than Aardvark Therapeutics. Aardvark Therapeutics is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$300K	96.29	-$28.74M	-$3.85	N/A
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A

Synaptogenix has a beta of 1.73, indicating that its share price is 73% more volatile than the broader market. Comparatively, Aardvark Therapeutics has a beta of 3.8, indicating that its share price is 280% more volatile than the broader market.

10.3% of Synaptogenix shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by insiders. Comparatively, 17.8% of Aardvark Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Aardvark Therapeutics beats Synaptogenix on 11 of the 16 factors compared between the two stocks.

Get Synaptogenix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TAOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TAOX vs. The Competition

Export

Metric	Synaptogenix	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$27.36M	$12.42B	$7.27B	$12.97B
Dividend Yield	N/A	2.63%	2.51%	22.89%
P/E Ratio	-0.91	807.81	275.40	25.37
Price / Sales	91.19	748.45	562.29	78.82
Price / Cash	N/A	86.65	77.16	53.04
Price / Book	1.23	9.21	10.55	5.95
Net Income	-$28.74M	$2.84B	$3.50B	$380.75M
7 Day Performance	-11.99%	-4.00%	-3.92%	-3.96%
1 Month Performance	-10.64%	-8.07%	-8.30%	-6.81%
1 Year Performance	-63.70%	-5.86%	2.35%	-4.58%

Synaptogenix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TAOX Synaptogenix	0.1507 of 5 stars	$3.49 -5.3%	N/A	-61.4%	$27.36M	$300K	N/A	4
NRXP NRx Pharmaceuticals	1.9027 of 5 stars	$2.87 -1.0%	$34.50 +1,102.1%	-13.5%	$124.27M	$1.23M	N/A	29
VTVT vTv Therapeutics	3.1653 of 5 stars	$30.33 -0.8%	$55.83 +84.1%	+29.4%	$119.50M	$1.02M	N/A	26	Analyst Forecast Gap Up
BGM BGM Group	0.5901 of 5 stars	$9.29 -0.5%	N/A	-96.5%	$117.90M	$37.92M	N/A	471	Short Interest Increase Gap Down
UNCY Unicycive Therapeutics	2.7205 of 5 stars	$4.19 -0.7%	$18.25 +335.6%	-16.9%	$116.69M	$680K	N/A	22	Trending News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TAOX) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Synaptogenix (TAOX) Competitors

TAOX vs. NRXP, VTVT, BGM, UNCY, and AARD

How does Synaptogenix compare to NRx Pharmaceuticals?

Summary

How does Synaptogenix compare to vTv Therapeutics?

Summary

How does Synaptogenix compare to BGM Group?

Summary

How does Synaptogenix compare to Unicycive Therapeutics?

Summary

How does Synaptogenix compare to Aardvark Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TAOX vs. The Competition

Synaptogenix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Synaptogenix (TAOX) Competitors

TAOX vs. NRXP, VTVT, BGM, UNCY, and AARD

How does Synaptogenix compare to NRx Pharmaceuticals?

Does the media refer more to NRXP or TAOX?

Which has better earnings and valuation, NRXP or TAOX?

Do analysts prefer NRXP or TAOX?

Which has more volatility and risk, NRXP or TAOX?

Is NRXP or TAOX more profitable?

Do institutionals and insiders hold more shares of NRXP or TAOX?

Summary

How does Synaptogenix compare to vTv Therapeutics?

Which has higher valuation and earnings, VTVT or TAOX?

Is VTVT or TAOX more profitable?

Do insiders and institutionals hold more shares of VTVT or TAOX?

Which has more volatility & risk, VTVT or TAOX?

Do analysts prefer VTVT or TAOX?

Does the media refer more to VTVT or TAOX?

Summary

How does Synaptogenix compare to BGM Group?

Does the media refer more to BGM or TAOX?

Which has preferable earnings & valuation, BGM or TAOX?

Do insiders & institutionals hold more shares of BGM or TAOX?

Do analysts rate BGM or TAOX?

Is BGM or TAOX more profitable?

Which has more risk and volatility, BGM or TAOX?

Summary

How does Synaptogenix compare to Unicycive Therapeutics?

Do insiders and institutionals believe in UNCY or TAOX?

Which has more risk & volatility, UNCY or TAOX?

Does the media prefer UNCY or TAOX?

Do analysts rate UNCY or TAOX?

Which has better earnings & valuation, UNCY or TAOX?

Is UNCY or TAOX more profitable?

Summary

How does Synaptogenix compare to Aardvark Therapeutics?

Is TAOX or AARD more profitable?

Do analysts rate TAOX or AARD?

Does the media prefer TAOX or AARD?

Which has preferable earnings and valuation, TAOX or AARD?

Which has more volatility and risk, TAOX or AARD?

Do institutionals and insiders believe in TAOX or AARD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TAOX vs. The Competition

Synaptogenix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools